|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
MXPA05003477A
(es)
*
|
2002-10-03 |
2005-07-22 |
Targegen Inc |
Agentes vasculo-estaticos y metodos de uso de los mismos.
|
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
AU2005231507B2
(en)
|
2004-04-08 |
2012-03-01 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
NZ588896A
(en)
|
2004-08-25 |
2012-05-25 |
Targegen Inc |
Heterocyclic compounds and methods of use
|
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
WO2006133411A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
WO2007053452A1
(en)
|
2005-11-01 |
2007-05-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US20070149508A1
(en)
*
|
2005-11-02 |
2007-06-28 |
Targegen, Inc. |
Six membered heteroaromatic inhibitors targeting resistant kinase mutations
|
|
HUE028588T2
(hu)
|
2005-12-13 |
2016-12-28 |
Incyte Holdings Corp |
Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2007127366A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
|
WO2008008234A1
(en)
*
|
2006-07-07 |
2008-01-17 |
Targegen, Inc. |
2-amino-5-substituted pyrimidine inhibitors
|
|
MX2009004426A
(es)
|
2006-10-23 |
2009-08-12 |
Cephalon Inc |
Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
|
|
CN101563324A
(zh)
|
2006-12-22 |
2009-10-21 |
弗·哈夫曼-拉罗切有限公司 |
螺-哌啶衍生物
|
|
TW200840581A
(en)
*
|
2007-02-28 |
2008-10-16 |
Astrazeneca Ab |
Novel pyrimidine derivatives
|
|
MX2009009117A
(es)
*
|
2007-03-01 |
2009-09-03 |
Supergen Inc |
Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
|
|
US7947698B2
(en)
|
2007-03-23 |
2011-05-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
EP2740731B1
(en)
|
2007-06-13 |
2016-03-23 |
Incyte Holdings Corporation |
Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
CN101796046A
(zh)
*
|
2007-07-16 |
2010-08-04 |
阿斯利康(瑞典)有限公司 |
嘧啶衍生物934
|
|
CN101903357A
(zh)
|
2007-07-17 |
2010-12-01 |
里格尔药品股份有限公司 |
作为pkc抑制剂的环状胺取代的嘧啶二胺
|
|
BRPI0815979A2
(pt)
|
2007-08-28 |
2017-06-13 |
Irm Llc |
compostos e composições com inibidores de quinase, bem como uso dos mesmos
|
|
CA2703519C
(en)
|
2007-11-09 |
2017-04-18 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
|
US20100310563A1
(en)
*
|
2007-11-30 |
2010-12-09 |
Bumm Thomas G P |
Methods for treating induced cellular proliferative disorders
|
|
ATE535515T1
(de)
|
2008-01-11 |
2011-12-15 |
Hoffmann La Roche |
Modulatoren für amyloid beta
|
|
RU2490015C2
(ru)
|
2008-02-22 |
2013-08-20 |
Райджел Фармасьютикалз, Инк. |
Применение 2,4-пиримидиндиаминов для лечения атеросклероза
|
|
KR101247840B1
(ko)
*
|
2008-02-22 |
2013-03-26 |
에프. 호프만-라 로슈 아게 |
아밀로이드 베타 조절제
|
|
CA2723358A1
(en)
*
|
2008-05-05 |
2009-11-12 |
Allison B. Reiss |
Method for improving cardiovascular risk profile of cox inhibitors
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
JP2011523646A
(ja)
|
2008-05-21 |
2011-08-18 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
キナーゼ阻害剤としてのリン誘導体
|
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
|
US8338439B2
(en)
*
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AU2009262068C1
(en)
|
2008-06-27 |
2015-07-02 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US20100029675A1
(en)
*
|
2008-07-25 |
2010-02-04 |
Hwang Soo-In |
Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
|
|
BRPI0917575A2
(pt)
*
|
2008-08-05 |
2019-09-24 |
Targegen Inc |
métodos de tratamento de talassemia
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
JP5502089B2
(ja)
|
2008-10-09 |
2014-05-28 |
エフ．ホフマン−ラ ロシュ アーゲー |
アミロイドβのモジュレーター
|
|
CN102209537A
(zh)
|
2008-11-10 |
2011-10-05 |
弗·哈夫曼-拉罗切有限公司 |
杂环γ分泌酶调节剂
|
|
WO2010077740A2
(en)
*
|
2008-12-09 |
2010-07-08 |
Cytokine Pharmasciences, Inc. |
Novel antiviral compounds, compositions, and methods of use
|
|
EP2396004A4
(en)
|
2009-02-11 |
2012-07-25 |
Reaction Biology Corp |
SELECTIVE KINASE HEMMER
|
|
US20120270237A9
(en)
*
|
2009-04-03 |
2012-10-25 |
Cellzone AG |
Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
|
|
WO2010118986A1
(en)
*
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
WO2010129802A1
(en)
*
|
2009-05-06 |
2010-11-11 |
Portola Pharmaceuticals, Inc. |
Inhibitors of jak
|
|
NZ596479A
(en)
*
|
2009-05-22 |
2014-01-31 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
BRPI1012108B8
(pt)
|
2009-05-22 |
2021-05-25 |
Incyte Corp |
composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
|
|
EP2448938B9
(en)
|
2009-06-29 |
2015-06-10 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
|
JP2012197231A
(ja)
*
|
2009-08-06 |
2012-10-18 |
Oncotherapy Science Ltd |
Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
TWI557127B
(zh)
*
|
2009-09-04 |
2016-11-11 |
百健Ｍａ公司 |
布魯頓氏酪胺酸激酶抑制劑
|
|
CA2771675A1
(en)
*
|
2009-09-11 |
2011-03-17 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
|
CN102713618B
(zh)
|
2009-09-16 |
2015-07-15 |
新基阿维罗米克斯研究公司 |
蛋白激酶复合物和抑制剂
|
|
AU2010308028A1
(en)
*
|
2009-10-15 |
2012-04-19 |
Pfizer Inc. |
Pyrrolo[2,3-d] pyrimidine compounds
|
|
MX2012005155A
(es)
|
2009-11-03 |
2012-08-31 |
Glaxosmithkline Llc |
Compuestos de quinazolina.
|
|
WO2011056739A1
(en)
*
|
2009-11-03 |
2011-05-12 |
Glaxosmithkline Llc |
Compounds and methods
|
|
JP5859454B2
(ja)
*
|
2009-12-14 |
2016-02-10 |
メルク・シャープ・エンド・ドーム・ベー・フェー |
Ｍｋ２インヒビター
|
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
CA2782720A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
JP5781537B2
(ja)
*
|
2009-12-23 |
2015-09-24 |
メディシス ファーマシューティカル コーポレイション |
ヒスタミンｈ４受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体
|
|
WO2011082285A1
(en)
|
2009-12-30 |
2011-07-07 |
Avila Therapeutics, Inc. |
Ligand-directed covalent modification of protein
|
|
CN102791131A
(zh)
*
|
2010-01-13 |
2012-11-21 |
葛兰素史密斯克莱有限责任公司 |
化合物和方法
|
|
US8486967B2
(en)
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
CA2792508C
(en)
|
2010-03-10 |
2018-01-16 |
Incyte Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
CA2795456A1
(en)
|
2010-03-30 |
2011-10-06 |
Novartis Ag |
Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
|
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
|
CN103154246B
(zh)
|
2010-05-14 |
2015-11-25 |
达那-法伯癌症研究所 |
用于治疗白血病的组合物和方法
|
|
CN103180318B
(zh)
|
2010-05-14 |
2017-05-10 |
达那-法伯癌症研究所 |
雄性避孕组合物以及使用方法
|
|
ES2606958T3
(es)
|
2010-05-14 |
2017-03-28 |
Dana-Farber Cancer Institute, Inc. |
Compuestos de tienotriazolodiazepina para tratar una neoplasia
|
|
EA202091303A3
(ru)
|
2010-05-21 |
2021-05-31 |
Инсайт Холдингс Корпорейшн |
Композиция ингибитора jak для местного применения
|
|
BR112012029647A2
(pt)
|
2010-05-21 |
2016-08-02 |
Chemilia Ab |
novos derivados de pirimidinas
|
|
WO2011149827A1
(en)
*
|
2010-05-24 |
2011-12-01 |
Glaxosmithkline Llc |
Compounds and methods
|
|
PH12013500246A1
(en)
|
2010-08-10 |
2019-10-11 |
Celgene Avilomics Res Inc |
Besylate salt of a btk inhibitor
|
|
JP5956999B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
BR112013010564B1
(pt)
|
2010-11-01 |
2021-09-21 |
Celgene Car Llc |
Compostos heterocíclicos e composições compreendendo os mesmos
|
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
EP2637502B1
(en)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
JP5961187B2
(ja)
|
2010-12-20 |
2016-08-02 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
US9108984B2
(en)
*
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
|
MX2013010898A
(es)
|
2011-03-24 |
2013-12-06 |
Chemilia Ab |
Novedoso derivados de la pirimidina.
|
|
US9126948B2
(en)
*
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
|
US9249124B2
(en)
|
2011-03-30 |
2016-02-02 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Aurora kinase inhibitors and methods of making and using thereof
|
|
EP2694486B1
(en)
|
2011-04-01 |
2018-01-10 |
University of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
EP3628665B1
(en)
*
|
2011-04-01 |
2022-11-02 |
University of Utah Research Foundation |
Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
|
|
AU2012250517B2
(en)
|
2011-05-04 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
MX389479B
(es)
|
2011-09-02 |
2025-03-20 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
WO2013059548A1
(en)
|
2011-10-19 |
2013-04-25 |
Sanofi |
Compositions and methods for treating cancer using jak2 inhibitor
|
|
JP2014532658A
(ja)
|
2011-10-28 |
2014-12-08 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
ブルトン型チロシンキナーゼ疾患または障害を治療する方法
|
|
CN102429901B
(zh)
*
|
2011-11-03 |
2013-11-06 |
合肥博太医药生物技术发展有限公司 |
吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治肾纤维化药物中的应用
|
|
ES2880109T3
(es)
|
2012-03-15 |
2021-11-23 |
Celgene Car Llc |
Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
|
|
JP6317320B2
(ja)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
上皮成長因子受容体キナーゼ阻害剤の塩
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
AR091273A1
(es)
*
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
EP2858500A4
(en)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
BRUTON TYROSINE KINASE HEMMER
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
US20150182490A1
(en)
|
2012-06-26 |
2015-07-02 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
JP6313772B2
(ja)
|
2012-10-04 |
2018-04-18 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤である置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
KR102194611B1
(ko)
|
2012-10-04 |
2020-12-23 |
유니버시티 오브 유타 리서치 파운데이션 |
티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
|
|
KR102242077B1
(ko)
|
2012-11-15 |
2021-04-20 |
인사이트 홀딩스 코포레이션 |
룩솔리티니브의 서방성 제형
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CN105188371A
(zh)
|
2013-02-08 |
2015-12-23 |
西建阿维拉米斯研究公司 |
Erk抑制剂及其用途
|
|
EP3489239B1
(en)
|
2013-03-06 |
2021-09-15 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
|
PT2970205T
(pt)
|
2013-03-14 |
2019-08-26 |
Tolero Pharmaceuticals Inc |
Inibidores da jak2 e da alk2 e métodos para a sua utilização
|
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
WO2014151761A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Ariad Pharmaceuticals, Inc. |
Novel choline kinase inhibitors
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
US9210831B2
(en)
|
2013-04-15 |
2015-12-08 |
International Business Machines Corporation |
Separable and integrated heat sinks facilitating cooling multi-compnent electronic assembly
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
ES2665421T3
(es)
*
|
2013-06-04 |
2018-04-25 |
Acturum Real Estate Ab |
Compuestos de pirimidina y su uso como moduladores de la gamma secretasa
|
|
BR112016001457A2
(pt)
|
2013-07-25 |
2017-08-29 |
Dana Farber Cancer Inst Inc |
Inibidores de fatores de transcrição e usos dos mesmos
|
|
WO2015021149A1
(en)
*
|
2013-08-06 |
2015-02-12 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibitors of ack1/tnk2 tyrosine kinase
|
|
MX376856B
(es)
|
2013-08-07 |
2025-03-07 |
Incyte Holdings Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
US11446309B2
(en)
|
2013-11-08 |
2022-09-20 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
|
|
HRP20181109T1
(hr)
|
2013-12-11 |
2018-11-02 |
Biogen Ma Inc. |
Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP3099693A4
(en)
|
2014-01-31 |
2017-08-16 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
WO2015117083A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
MX2016009974A
(es)
|
2014-01-31 |
2016-10-31 |
Dana Farber Cancer Inst Inc |
Derivados de diaminopirimidina bencensulfona y sus usos.
|
|
WO2015131113A1
(en)
|
2014-02-28 |
2015-09-03 |
Tensha Therapeutics, Inc. |
Treatment of conditions associated with hyperinsulinaemia
|
|
US9340540B2
(en)
|
2014-02-28 |
2016-05-17 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
|
US10106507B2
(en)
*
|
2014-08-03 |
2018-10-23 |
H. Lee Moffitt Cancer Center and Research Insitute, Inc. |
Potent dual BRD4-kinase inhibitors as cancer therapeutics
|
|
WO2016022970A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
RU2017104897A
(ru)
|
2014-08-08 |
2018-09-10 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Производные диазепана и их применения
|
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
|
TWI679205B
(zh)
|
2014-09-02 |
2019-12-11 |
日商日本新藥股份有限公司 |
吡唑并噻唑化合物及醫藥
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
UA122130C2
(uk)
|
2014-10-27 |
2020-09-25 |
Тенша Терапеутікс, Інк. |
Інгібітори бромодомену
|
|
WO2016068867A1
(en)
|
2014-10-28 |
2016-05-06 |
Cummins Emission Solutions, Inc. |
Scr conversion efficiency diagnostics
|
|
NZ731185A
(en)
|
2014-10-29 |
2024-03-22 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for mt1-mmp
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016138352A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
SG10201912302VA
(en)
|
2015-02-27 |
2020-02-27 |
Incyte Corp |
Salts of pi3k inhibitor and processes for their preparation
|
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US10494378B2
(en)
*
|
2015-07-21 |
2019-12-03 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd. |
Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CN118063537A
(zh)
|
2015-09-08 |
2024-05-24 |
莫纳什大学 |
定向淋巴的前药
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
US11306105B2
(en)
|
2015-09-11 |
2022-04-19 |
Dana-Farber Cancer Institute, Inc. |
Cyano thienotriazolodiazepines and uses thereof
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
WO2017066428A1
(en)
|
2015-10-13 |
2017-04-20 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Brd4-kinase inhibitors as cancer therapeutics
|
|
MX389001B
(es)
|
2015-10-23 |
2025-03-20 |
Navitor Pharm Inc |
Moduladores de interacción de sestrina-gator2 y sus usos.
|
|
CN108472298B
(zh)
|
2015-11-24 |
2021-04-20 |
深圳阿拉丁医疗科技有限公司 |
选择性激酶抑制剂
|
|
CR20180336A
(es)
|
2015-11-25 |
2018-08-06 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos
|
|
GB201521919D0
(en)
|
2015-12-11 |
2016-01-27 |
Electrophoretics Ltd |
Isobaric mass labels
|
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
|
PT3426243T
(pt)
|
2016-03-09 |
2021-08-19 |
Raze Therapeutics Inc |
Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
IL307931A
(en)
*
|
2016-04-15 |
2023-12-01 |
Epizyme Inc |
Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
|
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
EP3808748B1
(en)
|
2016-06-21 |
2026-05-20 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
|
JP6994767B2
(ja)
|
2016-06-21 |
2022-01-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
CA3031443A1
(en)
|
2016-07-21 |
2018-01-25 |
Biogen Ma Inc. |
Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
|
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
|
CN110300590A
(zh)
|
2016-10-21 |
2019-10-01 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
EP3559018A1
(en)
|
2016-12-23 |
2019-10-30 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
ES2985986T3
(es)
|
2017-01-06 |
2024-11-08 |
Bicyclerd Ltd |
Conjugado biciclo para tratar el cáncer
|
|
AU2018230737B2
(en)
|
2017-03-08 |
2022-09-22 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
US10363230B2
(en)
|
2017-03-23 |
2019-07-30 |
North Carolina Agricultural And Technical State University |
6-shogaol derivatives and activities thereof
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
WO2018195450A1
(en)
|
2017-04-21 |
2018-10-25 |
Epizyme, Inc. |
Combination therapies with ehmt2 inhibitors
|
|
ES3040534T3
(en)
|
2017-04-26 |
2025-11-03 |
Navitor Pharm Inc |
Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
|
|
EP3615550A1
(en)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
|
IL317854A
(en)
|
2017-07-28 |
2025-02-01 |
Takeda Pharmaceuticals Co |
TYK2 inhibitors and their uses
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
EP4306524A3
(en)
|
2017-08-29 |
2024-09-11 |
PureTech LYT, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020007152A
(es)
*
|
2017-10-18 |
2020-12-10 |
Epizyme Inc |
Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
EP3578555B1
(en)
*
|
2018-01-16 |
2022-09-21 |
Shenzhen TargetRx, Inc. |
Diphenylaminopyrimidine compound for inhibiting kinase activity
|
|
AU2019212969B2
(en)
|
2018-01-29 |
2025-01-23 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
CA3089762A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
MD3746429T2
(ro)
|
2018-01-30 |
2022-08-31 |
Incyte Corp |
Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
|
|
WO2019152883A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Padforward Llc |
Inhibitors of protein arginine deiminases
|
|
CA3091775A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
KR20260028873A
(ko)
|
2018-02-27 |
2026-03-04 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
|
KR20260080448A
(ko)
|
2018-03-30 |
2026-06-02 |
인사이트 코포레이션 |
Jak 억제제를 사용하는 화농성 한선염의 치료
|
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
|
KR102063155B1
(ko)
|
2018-04-11 |
2020-01-08 |
한국과학기술연구원 |
우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체
|
|
IL301501B2
(en)
|
2018-04-24 |
2024-10-01 |
Vertex Pharma |
Antiproliferation compounds and uses thereof
|
|
EP3784669B1
(en)
|
2018-04-24 |
2023-10-25 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
IL278889B2
(en)
|
2018-06-01 |
2025-11-01 |
Incyte Corp |
Dosing regimen for the treatment of pi3k related disorders
|
|
US10980784B2
(en)
|
2018-06-15 |
2021-04-20 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
MY209349A
(en)
*
|
2018-09-25 |
2025-07-03 |
Impact Biomedicines Inc |
Methods of treating myeloproliferative disorders
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
WO2020086816A1
(en)
|
2018-10-24 |
2020-04-30 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2020092015A1
(en)
*
|
2018-11-02 |
2020-05-07 |
University Of Rochester |
Therapeutic mitigation of epithelial infection
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CN111362922A
(zh)
*
|
2018-12-26 |
2020-07-03 |
上海喆邺生物科技有限公司 |
2,4-二氨基嘧啶衍生物及其用途
|
|
CA3126034A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
FR3092581A1
(fr)
*
|
2019-02-12 |
2020-08-14 |
Impact Biomedicines, Inc |
Formes cristallines d'un inhibiteur de jak2
|
|
US12559463B2
(en)
|
2019-02-12 |
2026-02-24 |
Impact Biomedicines Inc. |
Crystalline forms of a JAK2 inhibitor
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
JP2022525186A
(ja)
|
2019-03-15 |
2022-05-11 |
ザ ジェネラル ホスピタル コーポレイション |
Ｔｅａｄ転写因子新規小分子阻害剤
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2021091535A1
(en)
|
2019-11-05 |
2021-05-14 |
Constellation Pharmaceuticals, Inc. |
Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
|
|
WO2020256739A1
(en)
|
2019-06-21 |
2020-12-24 |
Constellation Pharmaceuticals, Inc. |
Methods of treating myeloproliferative disorders
|
|
WO2020257644A1
(en)
|
2019-06-21 |
2020-12-24 |
Constellation Pharmaceuticals, Inc. |
Methods of treating myeloproliferative disorders
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CA3150492A1
(en)
|
2019-09-11 |
2021-03-18 |
Donna L. Romero |
Usp30 inhibitors and uses thereof
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
CA3156007A1
(en)
|
2019-09-27 |
2021-04-01 |
Disc Medicine, Inc. |
METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US11306062B2
(en)
|
2019-10-29 |
2022-04-19 |
Johnson Matthey Public Limited |
Forms of fedratinib dihydrochloride
|
|
AU2020376950B2
(en)
|
2019-11-01 |
2026-06-11 |
Supernus Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
EP4069223A4
(en)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN111423419B
(zh)
*
|
2020-01-17 |
2021-12-17 |
温州医科大学 |
一种小分子化合物cyy-260及其在制备抗肿瘤药物中的应用
|
|
JP7810970B2
(ja)
|
2020-02-05 |
2026-02-04 |
シーポート・セラピューティクス・インコーポレイテッド |
神経ステロイドの脂質プロドラッグ
|
|
AR121506A1
(es)
|
2020-03-03 |
2022-06-08 |
Pic Therapeutics Inc |
Inhibidores del eif4e y sus usos
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
AU2021273014A1
(en)
|
2020-05-13 |
2022-11-17 |
AbbVie Deutschland GmbH & Co. KG |
Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
|
|
ES3075793T3
(en)
|
2020-05-13 |
2026-08-07 |
Disc Medicine Inc |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN113754591B
(zh)
*
|
2020-06-05 |
2024-01-05 |
山东大学 |
一种hdac、jak和bet三靶点抑制剂及其制备方法和应用
|
|
EP3944859A1
(en)
|
2020-07-30 |
2022-02-02 |
Assistance Publique Hôpitaux de Paris |
Method for treating immune toxicities induced by immune checkpoint inhibitors
|
|
CN116348476A
(zh)
|
2020-08-03 |
2023-06-27 |
拜斯科技术开发有限公司 |
基于肽的接头
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
CN112225703B
(zh)
*
|
2020-09-28 |
2022-03-11 |
广州智睿医药科技有限公司 |
一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
|
|
EP4232425A4
(en)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1 inhibitors and uses thereof
|
|
AU2021371697B2
(en)
*
|
2020-10-29 |
2024-10-24 |
Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
|
|
TWI750905B
(zh)
*
|
2020-11-19 |
2021-12-21 |
財團法人國家衛生研究院 |
噻唑化合物作為蛋白質激酶抑制劑
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
EP4262770A1
(en)
|
2020-12-16 |
2023-10-25 |
Impact Biomedicines, Inc. |
Dosing of fedratinib
|
|
US20240108633A1
(en)
*
|
2020-12-29 |
2024-04-04 |
Onquality Pharmaceuticals China Ltd. |
Method for preventing or treating disease or condition associated with antitumor agent
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
CN112778282B
(zh)
*
|
2021-01-06 |
2022-07-22 |
温州医科大学 |
一种嘧啶类小分子化合物及其应用
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
EP4297750A1
(en)
|
2021-02-25 |
2024-01-03 |
Impact Biomedicines, Inc. |
Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
KR102585194B1
(ko)
*
|
2021-03-26 |
2023-10-10 |
주식회사 스탠다임 |
Lrrk2에 대해 저해 활성을 갖는 신규한 페닐아미노피리미딘화합물 및 이의 용도
|
|
WO2022204721A1
(en)
*
|
2021-03-26 |
2022-09-29 |
Sumitomo Pharma Oncology, Inc. |
Alk-5 inhibitors and uses thereof
|
|
CN117355304A
(zh)
*
|
2021-03-26 |
2024-01-05 |
住友制药肿瘤公司 |
Alk-5抑制剂及其用途
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
US20240358722A1
(en)
|
2021-09-14 |
2024-10-31 |
Impact Biomedicines, Inc. |
Methods of administering fedratinib
|
|
EP4401735A4
(en)
*
|
2021-09-16 |
2025-07-16 |
Lomond Therapeutics Inc |
COMPOUNDS COMPRISING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
EP4238564A1
(en)
*
|
2022-03-02 |
2023-09-06 |
Bash Biotech Inc |
New treatments of renal cell carcinoma
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
CN119768393A
(zh)
|
2022-05-25 |
2025-04-04 |
医肯纳肿瘤学公司 |
Mek抑制剂和其用途
|
|
EP4565569A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
CN115745896B
(zh)
*
|
2022-11-18 |
2024-08-06 |
合肥医工医药股份有限公司 |
一种jak2激酶选择性抑制剂及其制备方法和用途
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
EP4673149A1
(en)
*
|
2023-03-02 |
2026-01-07 |
Trustlife Global Inc. |
New compounds and treatment of renal cell carcinoma
|
|
US20250059164A1
(en)
|
2023-06-23 |
2025-02-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4780462A1
(en)
|
2023-09-21 |
2026-07-29 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|